Biolexis management participated and presented pre-clinical data on CDK9 inhibitor at the AACR (American Association of Cancer Research) Annual Meeting on April 8-13, 2022, Ernest N. Morial Convention Center New Orleans, Louisiana.
B137 / 13 – Orally available, CDK9 selective, small molecule inhibitors shows promise in n-Myc-driven neuroendocrine prostate cancers (NEPC)
Session LBPO.MCB02 – Late-Breaking Research: Molecular/Cellular Biology and Genetics 2.
July 22-24, 2023 Biolexis Therapeutics CSO invited to Chair Cancer Immunology & Immunotherapy session and present MolecuLern technology at 14th Annual World Cancer Congress – WCC 11: Cancer Immunology & Immunotherapy on July 22-24, 2023, at Barcelona, Spain....
May 16-18, 2023 Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at 22nd Annual Bio-IT World Conference & Expo taking place May 16-18, 2023, in Boston, MA. https://www.bio-itworldexpo.com/
April 26-27, 2023 Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at Ai-Driven Drug Development Summit Europe on April 26-27, 2023, in London. AI Driven Drug Development Summit Europe 2023 (aidrugdevelopmentsummiteu.com)